💙 🔷 Not impressed by Big Tech in Q3? Explore these Blue Chip Bargains insteadUnlock them all

Haemonetics 3rd Quarter Fiscal Year 2024 Earnings Release Available on Investor Relations Website

Published 2024-02-08, 06:16 a/m
HAE
-

Financial release accessible online

BOSTON, Feb. 8, 2024 /PRNewswire/ -- Haemonetics (NYSE:HAE) Corporation (NYSE: HAE) announced that financial results for its third quarter fiscal year 2024, which ended December 30, 2023, are available on its Investor Relations website.

The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on February 8, 2024. The conference call and webcast can be accessed with the following information:

  • Teleconference link: https://register.vevent.com/register/BIddeef4a5eb8d4c2d96bcf82386d2a73e  
  • Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. While not required, it is recommended that participants join 10 minutes prior to the event start.
  • A live webcast of the call can be accessed on  Haemonetics' investor relations website or via the following link: https://edge.media-server.com/mmc/p/unynzc8w

In addition, the Company has posted to its Investor Relations website the earnings release that will be referenced on its conference call and webcast, a link to which is available below.  

Direct link to 3Q FY24 Earnings Release:
https://haemonetics.gcs-web.com/static-files/7edda7ff-7ea8-4178-b828-abcfcbafec7c  

A replay of the conference call and webcast will be available for one year beginning on February 8, 2024, at 11:00 a.m. ET using the conference call webcast link provided in this press release.

ABOUT HAEMONETICS
Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.

Investor Contacts:


Olga Guyette, Sr. Director-Investor Relations & Treasury

 David Trenk, Manager-Investor Relations

(781) 356-9763

 (203) 733-4987

olga.guyette@haemonetics.com

 david.trenk@haemonetics.com                                                                                                                                                              



Media Contact:


Josh Gitelson, Director-Global Communications


(781) 356-9776


josh.gitelson@haemonetics.com

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/haemonetics-3rd-quarter-fiscal-year-2024-earnings-release-available-on-investor-relations-website-302056960.html

SOURCE Haemonetics Corporation

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.